<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05037357</url>
  </required_header>
  <id_info>
    <org_study_id>SYSUCC-CMY-2021-EBV</org_study_id>
    <nct_id>NCT05037357</nct_id>
  </id_info>
  <brief_title>Verification of Harmonization of Plasma Epstein-Barr Virus DNA Measurements</brief_title>
  <official_title>Verification of Harmonization of Plasma Epstein-Barr Virus DNA Measurements at Multiple Centers in NPC Epidemic Regions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wuzhou Red Cross Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhongshan People's Hospital, Guangdong, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Plasma Epstein-Barr virus (EBV) DNA will be measured in native plasma samples of&#xD;
      nasopharyngeal carcinoma (NPC) patients, respectively, by three medical centers and a&#xD;
      qualified laboratory in Southern China, the highest endemic area of NPC. Passing-Bablok&#xD;
      regression and difference plots will be used to compare results from each center to the&#xD;
      all-method median and mean values. Agreement among methods will be evaluated against bias&#xD;
      derived from a biological variation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators intend to collect EBV DNA positive plasma samples of NPC patients,&#xD;
      distribute the samples to four test centers and compare the measurement results to obtain the&#xD;
      current status of the agreement of plasma EBV DNA measuring at different centers with various&#xD;
      measurement systems in the endemic regions of NPC. A series of statistical analyses including&#xD;
      Cohen's Kappa, intraclass correlation coefficient, and Passing-Bablok regression will be&#xD;
      adopted for the consistency test. A harmonization study by using the same calibrators will be&#xD;
      conducted.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2021</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma EBV DNA</measure>
    <time_frame>1 Day</time_frame>
    <description>copy number of EBV DNA in plasma</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">370</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>nasopharyngeal carcinoma patients</arm_group_label>
    <description>Plasma EBV DNA quantification by quantitative polymerase chain reaction (qPCR) assays in different medical centers.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Plasma EBV DNA qPCR test</intervention_name>
    <description>Peripheral blood will be collected from each subject into an EDTA tube for the isolation of plasma.</description>
    <arm_group_label>nasopharyngeal carcinoma patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Peripheral blood will be collected into ethylenediaminetetraacetic acid (EDTA)-coated tubes&#xD;
      and centrifuged, the plasma will be recovered and frozen at -80â„ƒ until the test.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        NPC patients or Plasma EBV DNA positive people&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age between 18-70 years&#xD;
&#xD;
          -  Histologically confirmed NPC or Non-NPC with positive plasma cell-free EBV DNA&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  unsatisfactory performance status: Karnofsky scale (KPS) &lt;= 70&#xD;
&#xD;
          -  Any severe intercurrent disease&#xD;
&#xD;
          -  Any contraindication of blood sampling&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ming-Yuan Chen, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ming-Yuan Chen, MD, PhD</last_name>
    <phone>86-20-8734-3361</phone>
    <email>chmingy@mail.sysu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Si-Yuan Chen, MD</last_name>
    <phone>86-18711150216</phone>
    <email>chensy@sysucc.org.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ming-Yuan Chen, MD, PhD</last_name>
      <phone>86-20-8734-3624</phone>
      <email>chmingy@mail.sysu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Ming-Yuan Chen, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 10, 2021</study_first_submitted>
  <study_first_submitted_qc>September 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 8, 2021</study_first_posted>
  <last_update_submitted>September 15, 2021</last_update_submitted>
  <last_update_submitted_qc>September 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Ming-Yuan Chen</investigator_full_name>
    <investigator_title>professor &amp; chief physician</investigator_title>
  </responsible_party>
  <keyword>Nasopharyngeal Carcinoma</keyword>
  <keyword>plasma EBV DNA</keyword>
  <keyword>Harmonization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

